“让我感到高兴的是，确定自己可以帮助这些家庭度过艰难时期，知道自己的努力能够带来改变。”
林成祥医生毕业于圣安德鲁斯大学和爱丁堡大学，并获得了医学学位（医学学士和外科学士）。随后，他移居纽约，在康奈尔大学医学院附属纽约医院和纪念斯隆·凯特琳癌症中心完成了内科学的研究生培训，随即完成了血液学和肿瘤内科学的培训。除了获得内科、肿瘤内科和血液病学的美国委员会认证外，林医生还是爱丁堡皇家内科医师学会会员。1998 年回到新加坡后，他对胃肠道肿瘤、肝癌和胰腺癌产生了特殊的临床兴趣。
除了在临床诊疗方面的技能外，他还是几项结肠癌和胰腺癌关键重大研究的合著者，这些研究影响了临床实践。从 2005 年至 2011 年，他担任了新加坡国立大学癌症研究所的血液病学—肿瘤学部门主任。尤其是他对着重开发新药物治疗和增强对亚洲癌症患者特殊问题的理解已帮助了许多患者及其家人。
他是肿瘤内科专科培训委员会委员，帮助培训众多内科和肿瘤科医生，并提供了宝贵的带教和指导。他还担任新加坡国立大学癌症中心的副主任，并且是托福园慈怀病院的前任理事，并担任了该院医疗专业审计委员会主席。
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Colorectal cancer
Phase II APEC trial: The impact of primary tumor side on outcomes of first‐line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild‐type metastatic colorectal cancer. Timothy Price, Lin Shen, Brigette Ma, Regina Esser, Wenfeng Chen, Peter Gibbs, Robert Lim, Ann‐Lii Cheng. Asia-Pacific Journal of Clinical Oncology 2019; 15: 225 -230.
Efficacy, tolerability, and biomarker analyses of once-every-2-weeks cetuximab plus first-line FOLFOX or FOLFIRI in patients with KRAS or all RAS wild-type metastatic colorectal cancer: the phase 2 APEC study. A.L. Cheng, Kensei Yamaguchi, M.D.; Gerardo Cornelio; Lin Shen; Timothy Price; Tsai-Sheng Yang; Ik Joo Chung; Guang-Hai Dai; Jen-Kou Lin; Atul Sharma; Kun-Huei Yeh; Brigette Ma; Adel Zaatar; Zhongzhen Guan; Nehal Masood; Vichien Srimuninnimit; Thomas Yau; Peter Gibbs; Xiuwen Wang; Dinesh Chandra Doval; Seung-Taek Oh; Byoung Yong Shim; Charity Gorospe; Hwei-Ming Wang; Ekaphop Sirachainan; Andrew Hill; Kwang Wook Suh; Frank Beier; Sudipto Chatterjee; Robert Lim. E Clin Colorectal Cancer 2016.
FOLFIRI plus either sunitinib or placebo in metastatic colorectal cancer: a phase III trial. A Carrato, A Swieboda-Sadlej, M Staszewska-Skurczynska, R Lim, L Roman, Y Shparyk, I Bondarenko, D Jonker, Y Sun, JA De la Cruz, JA Williams, B Korytowsky, X Lin, JM Tursi, MJ Lechuga, E Van Cutsem. Journal of Clinical Oncology 2013; 31 (10) 1341 – 1347.
Cetuximab plus irinotecan in patients from the Asia-Pacific region with pretreated metastatic colorectal cancer progressing on irinotecan: The ELSIE study. Robert Lim, Yan Sun, Seock-Ah Im, Ruey-Kuen Hsieh, Tsz Kok Yau, Anthony Bonaventura, Arkom Cheirsilpa, Regina Esser, Matthias Mueser, Suresh Advani. World Journal of Gastroenterology 2011; 17(14): 1879 – 1888.
FOLFIRI with and without cetuximab in the first-line treatment of metastatic colorectal cancer: efficacy, safety and KRAS Eric Van Cutsem, Istvan Lang, Jerzy Zaluski, Chung-Rong Chang Chien, Anatoly Makhson, Geert D’Haens, Tamás Pintér, Robert Lim, Győrgy Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Johannes Nippgen, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Philippe Rougier. The New England Journal of Medicine 2009; 360: 1408 -1417.
Phase II APEC trial: The impact of primary tumor side on outcomes of first‐line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild‐type metastatic colorectal cancer. Timothy Price, Lin Shen, Brigette Ma, Regina Esser, Wenfeng Chen, Peter Gibbs, Robert Lim, Ann‐Lii Cheng. Asia-Pacific Journal of Clinical Oncology 2019; 15: 225 -230.
Efficacy, tolerability, and biomarker analyses of once-every-2-weeks cetuximab plus first-line FOLFOX or FOLFIRI in patients with KRAS or all RAS wild-type metastatic colorectal cancer: the phase 2 APEC study. A.L. Cheng, Kensei Yamaguchi, M.D.; Gerardo Cornelio; Lin Shen; Timothy Price; Tsai-Sheng Yang; Ik Joo Chung; Guang-Hai Dai; Jen-Kou Lin; Atul Sharma; Kun-Huei Yeh; Brigette Ma; Adel Zaatar; Zhongzhen Guan; Nehal Masood; Vichien Srimuninnimit; Thomas Yau; Peter Gibbs; Xiuwen Wang; Dinesh Chandra Doval; Seung-Taek Oh; Byoung Yong Shim; Charity Gorospe; Hwei-Ming Wang; Ekaphop Sirachainan; Andrew Hill; Kwang Wook Suh; Frank Beier; Sudipto Chatterjee; Robert Lim. E Clin Colorectal Cancer 2016.
FOLFIRI plus either sunitinib or placebo in metastatic colorectal cancer: a phase III trial. A Carrato, A Swieboda-Sadlej, M Staszewska-Skurczynska, R Lim, L Roman, Y Shparyk, I Bondarenko, D Jonker, Y Sun, JA De la Cruz, JA Williams, B Korytowsky, X Lin, JM Tursi, MJ Lechuga, E Van Cutsem. Journal of Clinical Oncology 2013; 31 (10) 1341 – 1347.
Cetuximab plus irinotecan in patients from the Asia-Pacific region with pretreated metastatic colorectal cancer progressing on irinotecan: The ELSIE study. Robert Lim, Yan Sun, Seock-Ah Im, Ruey-Kuen Hsieh, Tsz Kok Yau, Anthony Bonaventura, Arkom Cheirsilpa, Regina Esser, Matthias Mueser, Suresh Advani. World Journal of Gastroenterology 2011; 17(14): 1879 – 1888.
FOLFIRI with and without cetuximab in the first-line treatment of metastatic colorectal cancer: efficacy, safety and KRAS Eric Van Cutsem, Istvan Lang, Jerzy Zaluski, Chung-Rong Chang Chien, Anatoly Makhson, Geert D’Haens, Tamás Pintér, Robert Lim, Győrgy Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Johannes Nippgen, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Philippe Rougier. The New England Journal of Medicine 2009; 360: 1408 -1417.